The pharmaceutical industry often operates like the rules don’t apply to it. Over the years, prescription drug manufacturers have been slapped with billions in fines after they are caught overstepping regulatory limits meant to protect patients and taxpayers. The most significant cases were initiated by whistleblowers, and thanks to them, greater transparency has been forced on the industry.

In the most recent blow, a Ninth Circuit Court of Appeals decision has revived a whistleblower lawsuit against Gilead Sciences. The ruling has put Big Pharma on edge. A federal district court had dismissed the case in 2015, saying the complaint had failed to state a claim that violated the False Clams Act.

Read more at Forbes